BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Legarda MA, Cejalvo MJ, de la Rubia J. Recent Advances in the Treatment of Patients with Multiple Myeloma. Cancers (Basel) 2020;12:E3576. [PMID: 33265952 DOI: 10.3390/cancers12123576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, Ria R, Catalano L, Tacchetti P, Mele G, Donatella Vincelli I, Antonia Martino E, Vigna E, Botta C, Bruzzese A, Mele A, Pantani L, Rocchi S, Garibaldi B, Cascavilla N, Ballanti S, Tripepi G, Frigeri F, Pia Falcone A, Cangialosi C, Reddiconto G, Farina G, Barone M, Rizzello I, Musto P, De Stefano V, Musso M, Teresa Petrucci M, Offidani M, Neri A, Di Renzo N, Di Raimondo F, Boccadoro M, Cavo M, Gentile M. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. Eur J Haematol 2021. [PMID: 34716957 DOI: 10.1111/ejh.13723] [Reference Citation Analysis]
2 Amodio N. Recent Advances on the Pathobiology and Treatment of Multiple Myeloma. Cancers (Basel) 2021;13:3112. [PMID: 34206430 DOI: 10.3390/cancers13133112] [Reference Citation Analysis]
3 Aksenova AY, Zhuk AS, Lada AG, Zotova IV, Stepchenkova EI, Kostroma II, Gritsaev SV, Pavlov YI. Genome Instability in Multiple Myeloma: Facts and Factors. Cancers (Basel) 2021;13:5949. [PMID: 34885058 DOI: 10.3390/cancers13235949] [Reference Citation Analysis]
4 Riva G, Nasillo V, Ottomano AM, Bergonzini G, Paolini A, Forghieri F, Lusenti B, Barozzi P, Lagreca I, Fiorcari S, Martinelli S, Maffei R, Marasca R, Potenza L, Comoli P, Manfredini R, Tagliafico E, Trenti T, Luppi M. Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. Cancers (Basel) 2021;13:4582. [PMID: 34572809 DOI: 10.3390/cancers13184582] [Reference Citation Analysis]
5 Murdaca G, Allegra A, Paladin F, Calapai F, Musolino C, Gangemi S. Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma. Int J Mol Sci 2021;22:9039. [PMID: 34445745 DOI: 10.3390/ijms22169039] [Reference Citation Analysis]
6 Schnog JB, Samson MJ, Gans ROB, Duits AJ. An urgent call to raise the bar in oncology. Br J Cancer 2021. [PMID: 34400802 DOI: 10.1038/s41416-021-01495-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ri M, Iida S, Maruyama D, Sakabe A, Kamei R, Nakashima T, Tohkin M, Osaga S, Tobinai K, Fukuhara N, Miyazaki K, Tsukamoto N, Tsujimura H, Yoshimitsu M, Miyamoto K, Tsukasaki K, Nagai H. HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1). Cancer Sci 2021. [PMID: 34626515 DOI: 10.1111/cas.15158] [Reference Citation Analysis]
8 Bębnowska D, Hrynkiewicz R, Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, Smarz-Widelska I, Góźdź S, Roliński J, Niedźwiedzka-Rystwej P. Immunological Prognostic Factors in Multiple Myeloma. Int J Mol Sci 2021;22:3587. [PMID: 33808304 DOI: 10.3390/ijms22073587] [Reference Citation Analysis]